Holen Sie sich die Stockscreener-App
17.87
4.39%
-0.82
Handel nachbörslich:
17.88
0.010
+0.06%
Schlusskurs vom Vortag:
$18.69
Offen:
$18
24-Stunden-Volumen:
479.84K
Relative Volume:
1.94
Marktkapitalisierung:
$915.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.21M
KGV:
-9.455
EPS:
-1.89
Netto-Cashflow:
$-68.53M
1W Leistung:
-9.20%
1M Leistung:
-14.90%
6M Leistung:
-34.90%
1J Leistung:
-7.89%
1-Tages-Spanne:
$16.99
$19.69
1-Wochen-Bereich:
$16.99
$20.33
52-Wochen-Spanne:
$15.96
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Vergleichen Sie ELVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
17.87 | 915.89M | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Eingeleitet | BTIG Research | Buy |
| 2024-09-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-09 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | Jefferies | Buy |
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? - MSN
Major Cancer Drug Breakthrough: Enliven Unveils Triple-Asset Data at AACR 2025 - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.9% After Insider Selling - Defense World
Enliven Therapeutics CFO Benjamin Hohl sells $69,320 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CFO Benjamin Hohl sells $69,320 in stock - Investing.com India
Where are the Opportunities in (ELVN) - news.stocktradersdaily.com
Swiss National Bank Increases Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics CFO sells $22,504 in stock By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO sells $22,504 in stock - Investing.com India
Charles Schwab Investment Management Inc. Grows Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Bank of New York Mellon Corp Sells 828 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics chief scientific officer sells $257,575 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics chief scientific officer sells $257,575 in stock - Investing.com India
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory - Marketscreener.com
(ELVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Lifesci Capital Issues Optimistic Forecast for ELVN Earnings - Defense World
Enliven Therapeutics CEO Samuel Kintz sells $260,320 in stock - Investing.com
Enliven Therapeutics CEO Samuel Kintz sells $260,320 in stock By Investing.com - Investing.com UK
Decoding Enliven Therapeutics Inc (ELVN): A Strategic SWOT Insig - GuruFocus.com
Enliven grew fourth-quarter R&D spending with trials underway - BizWest
Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline - Value The Markets
Enliven Therapeutics Reports 2024 Financial Results - TipRanks
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - Citizentribune
Enliven Therapeutics Inc. (ELVN) reports earnings - Quartz
Enliven Therapeutics Q4 Operating Expenses USD 26.896 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
ENLIVEN THERAPEUTICS Earnings Results: $ELVN Reports Quarterly Earnings - Nasdaq
Enliven Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (ELVN) Enliven Therapeutics Posts Q4 Loss $-0.46 Per Share -March 13, 2025 at 04:12 pm EDT - Marketscreener.com
Enliven Therapeutics Secures 3-Year Runway with $313M War Chest, Advances Cancer Drug Pipeline - Stock Titan
Enliven Therapeutics COO Anish Patel sells $142,936 in stock - Investing.com
Enliven Therapeutics COO Anish Patel sells $142,936 in stock By Investing.com - Investing.com Australia
(ELVN) Investment Analysis and Advice - Stock Traders Daily
Enliven Therapeutics (ELVN) Projected to Post Quarterly Earnings on Thursday - Defense World
New York State Common Retirement Fund Sells 2,488 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics CFO Sells Shares - TradingView
Enliven Therapeutics CFO sells $22,524 in stock - MSN
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Longview News-Journal
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap DownHere's Why - MarketBeat
(ELVN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $146,207.31 in Stock - MarketBeat
Enliven Therapeutics COO Anish Patel sells $146,205 in stock - MSN
Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat
Enliven Therapeutics COO Anish Patel sells $146,205 in stock By Investing.com - Investing.com South Africa
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Enliven Therapeutics Inc-Aktie (ELVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Mar 27 '25 |
Sale |
21.33 |
3,250 |
69,321 |
23,000 |
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):